Opportunities to engage with STAT reporters and leading industry experts
Join the conversation! Every Tuesday at 1 p.m. ET, STAT+ subscribers get access to exclusive virtual conversations with biotech, pharma and health tech leaders. Register below for this month’s conversations, brought to you by Kalderos. And don’t forget, you can view past conversations as well.
DECEMBER 7, 2021
The ‘Shroom Boom’
The potential of the psychedelics industry has never been bigger. Long-stigmatized drugs are advancing through clinical trials for treatments of mental health conditions. Olivia Goldhill explored this booming industry, highlighting the opportunities for growth and the potential barriers, in the latest STAT Report. Join for a discussion on what she found.
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.
What's included?
- Daily reporting and analysis
- The most comprehensive industry coverage from a powerhouse team of reporters
- Subscriber-only newsletters
- Daily newsletters to brief you on the most important industry news of the day
- STAT+ Conversations
- Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
- Exclusive industry events
- Premium access to subscriber-only networking events around the country
- The best reporters in the industry
- The most trusted and well-connected newsroom in the health care industry
- And much more
- Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
